Accelerate Diagnostics (NASDAQ:AXDX) Posts Earnings Results

Accelerate Diagnostics (NASDAQ:AXDXGet Rating) released its quarterly earnings results on Monday. The medical research company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.09, MarketWatch Earnings reports. During the same quarter in the previous year, the business posted ($0.41) EPS.

Shares of Accelerate Diagnostics stock traded down $0.00 during trading hours on Wednesday, hitting $0.60. The company’s stock had a trading volume of 8,415 shares, compared to its average volume of 670,667. Accelerate Diagnostics has a 12-month low of $0.58 and a 12-month high of $9.36. The business has a 50 day moving average price of $1.22 and a two-hundred day moving average price of $3.20.

In related news, CFO Steven Reichling sold 29,915 shares of the firm’s stock in a transaction on Thursday, April 28th. The shares were sold at an average price of $0.98, for a total transaction of $29,316.70. Following the completion of the transaction, the chief financial officer now directly owns 62,493 shares of the company’s stock, valued at $61,243.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jack Phillips sold 83,708 shares of the business’s stock in a transaction on Thursday, April 28th. The stock was sold at an average price of $0.98, for a total transaction of $82,033.84. Following the completion of the sale, the chief executive officer now owns 208,073 shares in the company, valued at approximately $203,911.54. The disclosure for this sale can be found here. Insiders have sold 128,695 shares of company stock valued at $126,121 in the last quarter. 42.20% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of AXDX. BNP Paribas Arbitrage SA increased its stake in Accelerate Diagnostics by 415.6% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 6,213 shares of the medical research company’s stock worth $36,000 after acquiring an additional 5,008 shares during the last quarter. Citigroup Inc. increased its position in Accelerate Diagnostics by 101.3% in the fourth quarter. Citigroup Inc. now owns 8,814 shares of the medical research company’s stock worth $46,000 after purchasing an additional 4,436 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Accelerate Diagnostics during the fourth quarter valued at $58,000. Invesco Ltd. bought a new position in Accelerate Diagnostics during the second quarter valued at $92,000. Finally, Two Sigma Investments LP purchased a new position in shares of Accelerate Diagnostics in the 3rd quarter worth $77,000. Institutional investors own 65.50% of the company’s stock.

Several research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 25th. Craig Hallum decreased their price objective on Accelerate Diagnostics to $1.00 and set an “underperform” rating on the stock in a research note on Tuesday. William Blair reiterated an “outperform” rating on shares of Accelerate Diagnostics in a research note on Wednesday, March 9th. Finally, StockNews.com assumed coverage on shares of Accelerate Diagnostics in a research note on Thursday, March 31st. They set a “sell” rating on the stock.

Accelerate Diagnostics Company Profile (Get Rating)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Stories

Earnings History for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.